Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference

Rhea-AI Summary

Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced that CEO Adrian Gottschalk will participate in the virtual Evercore ISI HealthCONx Conference on November 30, 2022, at 2:40 p.m. ET. The company focuses on gene expression treatments for serious diseases, particularly in oncology, using its Gene Traffic Control platform. The event will include a fireside chat, and a webcast will be available on the company's website for 90 days. Foghorn is developing innovative medicines that target chromatin regulatory systems.

CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Foghorn^® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Adrian Gottschalk, President and Chief Executive Officer, will participate in the Evercore ISI HealthCONx Conference which will be held virtually on November 30, 2022. With an initial focus in oncology, Foghorn’s Gene Traffic Control^® Platform and resulting broad pipeline have the potential to transform the lives of people with a wide spectrum of diseases.

Fireside chat date and time: Wednesday, November 30, 2022, at 2:40 p.m. ET

Please find a link to the fireside chat here.        

A webcast of the fireside chat and presentation will be accessible under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will remain available for up to 90 days.

About Foghorn Therapeutics
Foghorn Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary and scalable Gene Traffic Control platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology with two currently being investigated in clinical studies. Visit our website at www.foghorntx.com for more information on the company, and follow us on Twitter and LinkedIn.

Contact:

Ben Strain, Foghorn Therapeutics Inc. (Media and Investors)
bstrain@foghorntx.com 

Karin Hellsvik, Foghorn Therapeutics Inc. (Media)
khellsvik@foghorntx.com 

Michael Lampe, ScientPR (Media)
michael@scientpr.com 

Hans Vitzthum, LifeSci Advisors (Investors)
hans@lifesciadvisors.com 

FAQ

When is Foghorn Therapeutics participating in the Evercore ISI HealthCONx Conference?

Foghorn Therapeutics will participate in the Evercore ISI HealthCONx Conference on November 30, 2022.

Who will represent Foghorn Therapeutics at the conference?

Adrian Gottschalk, President and CEO of Foghorn Therapeutics, will represent the company.

What is the focus of Foghorn Therapeutics?

Foghorn Therapeutics focuses on developing treatments for serious diseases through gene expression correction, primarily in oncology.

How can I access the webcast of the event?

The webcast of the event will be available on Foghorn Therapeutics’ website under 'Events & Presentations'.

What is the significance of the Gene Traffic Control platform for Foghorn Therapeutics?

The Gene Traffic Control platform allows Foghorn Therapeutics to target and correct abnormal gene expression, demonstrating potential in treating a range of diseases.